JP7376490B2 - ＩｇＭ血清半減期に影響を及ぼすＩｇＭ Ｆｃ及びＪ鎖の変異 - Google Patents

ＩｇＭ血清半減期に影響を及ぼすＩｇＭ Ｆｃ及びＪ鎖の変異 Download PDF

Info

Publication number
JP7376490B2
JP7376490B2 JP2020543995A JP2020543995A JP7376490B2 JP 7376490 B2 JP7376490 B2 JP 7376490B2 JP 2020543995 A JP2020543995 A JP 2020543995A JP 2020543995 A JP2020543995 A JP 2020543995A JP 7376490 B2 JP7376490 B2 JP 7376490B2
Authority
JP
Japan
Prior art keywords
igm
antibody
seq
amino acid
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020543995A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514618A5 (enExample
JP2021514618A (ja
Inventor
ラメシュ バリガ
ブルース アラン キート
ディーン エング
Original Assignee
アイジーエム バイオサイエンシズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイジーエム バイオサイエンシズ インコーポレイテッド filed Critical アイジーエム バイオサイエンシズ インコーポレイテッド
Publication of JP2021514618A publication Critical patent/JP2021514618A/ja
Publication of JP2021514618A5 publication Critical patent/JP2021514618A5/ja
Priority to JP2023183845A priority Critical patent/JP2024016093A/ja
Application granted granted Critical
Publication of JP7376490B2 publication Critical patent/JP7376490B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2020543995A 2018-03-01 2019-03-01 ＩｇＭ血清半減期に影響を及ぼすＩｇＭ Ｆｃ及びＪ鎖の変異 Active JP7376490B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023183845A JP2024016093A (ja) 2018-03-01 2023-10-26 ＩｇＭ血清半減期に影響を及ぼすＩｇＭ Ｆｃ及びＪ鎖の変異

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862637186P 2018-03-01 2018-03-01
US62/637,186 2018-03-01
PCT/US2019/020374 WO2019169314A1 (en) 2018-03-01 2019-03-01 IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023183845A Division JP2024016093A (ja) 2018-03-01 2023-10-26 ＩｇＭ血清半減期に影響を及ぼすＩｇＭ Ｆｃ及びＪ鎖の変異

Publications (3)

Publication Number Publication Date
JP2021514618A JP2021514618A (ja) 2021-06-17
JP2021514618A5 JP2021514618A5 (enExample) 2022-03-07
JP7376490B2 true JP7376490B2 (ja) 2023-11-08

Family

ID=67805543

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020543995A Active JP7376490B2 (ja) 2018-03-01 2019-03-01 ＩｇＭ血清半減期に影響を及ぼすＩｇＭ Ｆｃ及びＪ鎖の変異
JP2023183845A Pending JP2024016093A (ja) 2018-03-01 2023-10-26 ＩｇＭ血清半減期に影響を及ぼすＩｇＭ Ｆｃ及びＪ鎖の変異

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023183845A Pending JP2024016093A (ja) 2018-03-01 2023-10-26 ＩｇＭ血清半減期に影響を及ぼすＩｇＭ Ｆｃ及びＪ鎖の変異

Country Status (11)

Country Link
US (3) US10899835B2 (enExample)
EP (1) EP3758752A4 (enExample)
JP (2) JP7376490B2 (enExample)
KR (1) KR102745232B1 (enExample)
CN (1) CN111787951B (enExample)
AU (2) AU2019227984A1 (enExample)
BR (1) BR112020017296A2 (enExample)
IL (1) IL276590A (enExample)
MX (1) MX2020009069A (enExample)
SG (1) SG11202008343YA (enExample)
WO (1) WO2019169314A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3105250B1 (en) 2014-02-10 2020-08-05 IGM Biosciences, Inc. Iga multi-specific binding molecules
PL3560954T3 (pl) 2014-04-03 2021-12-13 Igm Biosciences, Inc. Zmodyfikowany łańcuch J
IL308212A (en) 2015-01-20 2024-01-01 Igm Biosciences Inc Tumor necrosis factor-α receptor binding molecules and their uses
EP3957738A1 (en) 2015-03-04 2022-02-23 IGM Biosciences, Inc. Cd20 binding molecules and uses thereof
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
CN107847591B (zh) 2015-04-17 2023-07-28 Igm生物科学股份有限公司 多价人免疫缺陷病毒抗原结合分子及其应用
EP3355913B1 (en) 2015-09-30 2024-10-30 IGM Biosciences, Inc. Binding molecules with modified j-chain
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
SG11201809336QA (en) 2016-05-09 2018-11-29 Igm Biosciences Inc Anti-pd-l1 antibodies
MX2019011986A (es) 2017-04-07 2019-11-07 Igm Biosciences Inc Regiones constantes de igm humana modificadas para la modulacion de la funcion efectora de la citolisis dependiente de complemento referencia cruzada a solicitudes relacionadas.
MX2020009069A (es) 2018-03-01 2020-10-08 Igm Biosciences Inc Mutaciones de fc de igm y de la cadena j que afectan la semivida de igm en suero.
JP2022544405A (ja) 2019-08-15 2022-10-18 アイジーエム バイオサイエンシズ インコーポレイテッド 免疫刺激性多量体型結合分子
KR20220045030A (ko) * 2019-08-17 2022-04-12 아이쥐엠 바이오사이언스 인코포레이티드 다량체성 이중특이적 항-cd123 결합 분자 및 이의 용도
AU2020351205A1 (en) * 2019-09-19 2022-04-14 Igm Biosciences, Inc. Multimeric antibodies with enhanced selectivity for cells with high target density
CN110669134A (zh) * 2019-10-15 2020-01-10 广东菲鹏生物有限公司 IgM-FC片段、IgM-FC抗体及制备方法和应用
BR112022013071A2 (pt) * 2020-01-06 2022-09-20 Igm Biosciences Inc Moléculas de ligação multiméricas altamente sialiladas
EP4139362A2 (en) 2020-04-22 2023-03-01 IGM Biosciences Inc. Pd-1 agonist multimeric binding molecules
JP2023526224A (ja) * 2020-05-12 2023-06-21 アイジーエム バイオサイエンシズ インコーポレイテッド がんを治療するための、がん治療薬との組合せでの多量体抗ｄｒ５結合分子の使用
US20220033851A1 (en) * 2020-08-03 2022-02-03 Roger B. Swartz mRNA, episomal and genomic integrated lentiviral and gammaretroviral vector expression of dimeric immunoglobulin A and polymeric immunoglobulin A to Enable Mucosal and Hematological Based Immunity/Protection via Gene Therapy for Allergens, viruses, HIV, bacteria, pneumonia, infections, pathology associated proteins, systemic pathologies, cancer, toxins and unnatural viruses. CAR engineered and non-CAR engineered immune cell expression of dimeric immunoglobulin A and polymeric immunoglobulin A.
WO2022080912A1 (ko) * 2020-10-16 2022-04-21 주식회사 아이엠바이오로직스 IgM 영역을 이용한 융합단백질 플랫폼
US20240076392A1 (en) * 2021-02-17 2024-03-07 Igm Biosciences, Inc. Anti-cd123 binding molecules and uses thereof
EP4403569A4 (en) * 2021-09-13 2025-10-29 Shenyang Eye Industry Tech Institute Ltd Humanized Monoclonal Antibody Against Periostin, Method of Preparation Thereof and Its Use
WO2023064766A1 (en) * 2021-10-11 2023-04-20 Igm Biosciences, Inc. Lateral flow device and uses thereof
US20250326844A1 (en) 2022-04-07 2025-10-23 Repertoire Immune Medicines, Inc. T cell receptor multimers and uses thereof
AU2023253516A1 (en) * 2022-04-15 2024-11-21 Imbiologics Corp. Fusion protein platform with improved half-life
CN121405820A (zh) * 2025-12-29 2026-01-27 江苏谱新生物医药有限公司 一种病毒包膜嵌合受体及其相关生物材料和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000507816A (ja) 1996-03-18 2000-06-27 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
JP2001511122A (ja) 1997-01-10 2001-08-07 エピサイト ファーマシューティカル，インコーポレイテッド 新規な上皮組織標的化薬剤
JP2011528035A (ja) 2008-07-14 2011-11-10 ユーシカゴ アルゴン， エルエルシー タンパク質の安定性を体系的に制御するための方法
JP2016514675A (ja) 2013-03-15 2016-05-23 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド フラビウイルス中和抗体およびその使用方法
WO2017059380A1 (en) 2015-09-30 2017-04-06 Igm Biosciences, Inc. Binding molecules with modified j-chain

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6045774A (en) * 1997-01-10 2000-04-04 Epicyte Pharmaceutical Inc. J chain polypeptide targeting molecule linked to an imaging agent
US20050129616A1 (en) 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20040248299A1 (en) 2002-12-27 2004-12-09 Sumedha Jayasena RNA interference
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
DK1814913T3 (en) 2004-11-05 2015-09-28 Univ Leland Stanford Junior ANTIBODY-INDUCED CELL membrane damage.
BRPI0611445A2 (pt) * 2005-05-09 2010-09-08 Glycart Biotechnology Ag molécula de ligação a antìgeno glicomanipulada, polinucleotìdeo, polipeptìdeo, vetor, célula hospedeira, método para produção, uso e composição farmacêutica
JP5898082B2 (ja) * 2009-10-07 2016-04-06 マクロジェニクス，インコーポレーテッド フコシル化程度の変更により改良されたエフェクター機能を示すＦｃ領域含有ポリペプチドおよびその使用法
WO2013120012A2 (en) 2012-02-08 2013-08-15 Igm Biosciences Inc. Cdim binding proteins and uses thereof
CA2922830A1 (en) 2013-09-05 2015-04-16 Igm Biosciences, Inc. Constant chain modified bispecific, penta- and hexavalent ig-m antibodies
EP3105250B1 (en) 2014-02-10 2020-08-05 IGM Biosciences, Inc. Iga multi-specific binding molecules
PL3560954T3 (pl) 2014-04-03 2021-12-13 Igm Biosciences, Inc. Zmodyfikowany łańcuch J
IL308212A (en) 2015-01-20 2024-01-01 Igm Biosciences Inc Tumor necrosis factor-α receptor binding molecules and their uses
EP3957738A1 (en) 2015-03-04 2022-02-23 IGM Biosciences, Inc. Cd20 binding molecules and uses thereof
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
CN107847591B (zh) 2015-04-17 2023-07-28 Igm生物科学股份有限公司 多价人免疫缺陷病毒抗原结合分子及其应用
CN108025322B (zh) * 2015-07-09 2021-04-13 分配技术有限公司 用于流体的剂量分配的系统和制造方法
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
SG11201809336QA (en) 2016-05-09 2018-11-29 Igm Biosciences Inc Anti-pd-l1 antibodies
JP2019530640A (ja) 2016-07-20 2019-10-24 アイジーエム バイオサイエンシズ インコーポレイテッド 多量体ｏｘ４０結合分子及びその使用
AU2017299608A1 (en) 2016-07-20 2019-02-07 Igm Biosciences, Inc. Multimeric CD137/4-1BB binding molecules and uses thereof
MX2019000799A (es) 2016-07-20 2019-06-03 Igm Biosciences Inc Moleculas de union a gitr multimericas y usos de las mismas.
EP3496536A4 (en) 2016-07-20 2020-02-12 IGM Biosciences, Inc. MULTIMERE CD40-BINDING MOLECULES AND USES THEREOF
MX2019011986A (es) 2017-04-07 2019-11-07 Igm Biosciences Inc Regiones constantes de igm humana modificadas para la modulacion de la funcion efectora de la citolisis dependiente de complemento referencia cruzada a solicitudes relacionadas.
EP3759229A4 (en) 2018-02-26 2021-12-29 IGM Biosciences Inc. Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer
MX2020009069A (es) 2018-03-01 2020-10-08 Igm Biosciences Inc Mutaciones de fc de igm y de la cadena j que afectan la semivida de igm en suero.
US20210380701A1 (en) * 2018-10-23 2021-12-09 Igm Biosciences, Inc. MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES
US20220106398A1 (en) * 2019-02-08 2022-04-07 Igm Biosciences, Inc. Anti-gitr antigen-binding domains and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000507816A (ja) 1996-03-18 2000-06-27 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
JP2001511122A (ja) 1997-01-10 2001-08-07 エピサイト ファーマシューティカル，インコーポレイテッド 新規な上皮組織標的化薬剤
JP2011528035A (ja) 2008-07-14 2011-11-10 ユーシカゴ アルゴン， エルエルシー タンパク質の安定性を体系的に制御するための方法
JP2016514675A (ja) 2013-03-15 2016-05-23 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド フラビウイルス中和抗体およびその使用方法
WO2017059380A1 (en) 2015-09-30 2017-04-06 Igm Biosciences, Inc. Binding molecules with modified j-chain

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Vire, B. et al.，"TOSO, the Fcmicro receptor, is highly expressed on chronic lymphocytic leukemia B cells, internalizes upon IgM binding, shuttles to the lysosome, and is downregulated in response to TLR activation"，J. Immunol.，2011年，Vol. 187，pp. 4040-4050

Also Published As

Publication number Publication date
CN111787951B (zh) 2025-06-17
CN111787951A (zh) 2020-10-16
CA3091144A1 (en) 2019-09-06
JP2021514618A (ja) 2021-06-17
AU2019227984A1 (en) 2020-09-10
WO2019169314A1 (en) 2019-09-06
US20210087273A1 (en) 2021-03-25
KR20200128391A (ko) 2020-11-12
MX2020009069A (es) 2020-10-08
KR102745232B1 (ko) 2024-12-26
US20200239572A1 (en) 2020-07-30
IL276590A (en) 2020-09-30
EP3758752A1 (en) 2021-01-06
BR112020017296A2 (pt) 2020-12-29
SG11202008343YA (en) 2020-09-29
US10899835B2 (en) 2021-01-26
US20240124584A1 (en) 2024-04-18
JP2024016093A (ja) 2024-02-06
EP3758752A4 (en) 2021-12-15
AU2025271120A1 (en) 2026-01-22

Similar Documents

Publication Publication Date Title
JP7376490B2 (ja) ＩｇＭ血清半減期に影響を及ぼすＩｇＭ Ｆｃ及びＪ鎖の変異
US20230203173A1 (en) Tumor necrosis factor (tnf) superfamily receptor igm antibodies and uses thereof
KR20230005228A (ko) Pd-1 효능제 다량체 결합 분자
US20220306760A1 (en) Igm glycovariants
JP2024508709A (ja) 抗ｃｄ１２３結合分子及びその使用法
CA3091144C (en) Igm fc and j-chain mutations that affect igm serum half-life
CA3088131A1 (en) Methods and compositions for treating hpa hyperactivity
CA2972990C (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
HK40043005A (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
HK1242348B (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
HK1242348A1 (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200819

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231003

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231017

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231026

R150 Certificate of patent or registration of utility model

Ref document number: 7376490

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150